A Multicenter, Open-label, Randomized Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First- Line Treatment of Subjects with Advanced Renal Cell Carcinoma (16145)

A Multicenter, Open-label, Randomized Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First- Line Treatment of Subjects with Advanced Renal Cell Carcinoma (16145)

Trial Category:
Genitourinary
Phase
III
Contact(s)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Location(s)
Nebraska Cancer Specialists, Omaha, NE
 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members